<div id="readability-page-1"><p>TD Cowen analyst Daniel Brennan reiterated a Buy rating on GRAIL Inc yesterday and set a price target of $69.00.</p><h3>Claim 55% Off TipRanks</h3><ul><li>Unlock  hedge fund-level data  and  powerful investing tools  for smarter, sharper decisions  </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with  Smart Investor Picks  </li></ul> <p>Daniel Brennan has given his Buy rating due to a combination of factors, including stronger‑than‑expected first‑quarter performance and robust uptake of the Galleri test. Revenue and Galleri sales modestly surpassed forecasts on the back of roughly 50% volume growth, expanding prescriber adoption, and improving gross margins, supporting confidence in the company’s commercial trajectory and cash position.</p> <p>Brennan’s constructive stance also reflects upcoming clinical and regulatory catalysts that could further validate Galleri and expand its market opportunity. He highlights extensive data releases at ASCO, encouraging expert feedback on stage‑shift benefits, ongoing dialogue with the FDA, and positive expectations for oncologist receptivity, all of which underpin his upwardly revised $69 price target and support the Buy recommendation.</p> </div>

GRAL

LABU

SBIO

ARKG

IDNA

<p>TD Cowen analyst Daniel Brennan has reiterated a Buy rating on GRAIL Inc, raising the price target to $69. This decision is based on strong first-quarter performance, robust uptake of the Galleri test, and a 50% growth in volume. Upcoming clinical and regulatory catalysts, including data releases at ASCO and positive feedback from oncologists, further support his optimistic outlook on the company's market potential and cash position.</p>

Tip Ranks

GRAIL

Direxion S&P Biotech Bull 3X

ALPS Medical Breakthrough

Ark Genomic Revolution ETF

SPDR S&P Biotech

iShares Biotechnology ETF

iShares Genomics Immunology and Healthcare ETF

VanEck Biotech ETF

First Trust NYSE Arca Biotech Index Fd

Proshares Ultra Nasdaq Biotech

Daniel Brennan Reiterates Buy on Strong Galleri Momentum, Clinical Catalysts, and Raises Price Target to $69